Michael Barbella, Managing Editor09.30.23
Supply chains, silicon tech, and secrets were the top-rated topics on MPO's website this past week.
After a brief respite, MPO's 2023 top companies report returned to favor, though it was topped traffic-wise by the start of patient enrollment in Cardiosense's SEISMIC-HF I trial, a nationwide clinical study to refine and validate algorithms to assess intracardiac filling pressure, an early physiological marker for acute heart failure decompensation. The algorithms use data captured by Cardiosense’s non-invasive CardioTag patch, which measures key cardiac function parameters.
The magazine's first-ever supply chain survey polled well with readers, as it topped news from both Exo and Philips. Not surprisingly, the survey results garnered more pageviews than Exo's release of Exo Iris, a handheld ultrasound device that aims to put high-performance medical imaging into caregivers' hands and pockets. And the Exo Iris release—curiously—enticed more cybervisitors than Philips' ongoing sleep therapy device troubles (perhaps readers are growing weary of the saga?). A ProPublica and Pittsburgh Gazette investigation claims the company knew about the health risks of its degraded PE-PUR sound abatement foam in its respiratory devices as early as 2010—11 years before it became a major recall. ProPublica claims that Philips received reports early on warning of “black particles” or “dirt and dust” inside the devices’ airway chambers, yet withheld most of the warnings from the FDA "to protect its marquee products as stock prices soared to the highest level in decades."
After a brief respite, MPO's 2023 top companies report returned to favor, though it was topped traffic-wise by the start of patient enrollment in Cardiosense's SEISMIC-HF I trial, a nationwide clinical study to refine and validate algorithms to assess intracardiac filling pressure, an early physiological marker for acute heart failure decompensation. The algorithms use data captured by Cardiosense’s non-invasive CardioTag patch, which measures key cardiac function parameters.
The magazine's first-ever supply chain survey polled well with readers, as it topped news from both Exo and Philips. Not surprisingly, the survey results garnered more pageviews than Exo's release of Exo Iris, a handheld ultrasound device that aims to put high-performance medical imaging into caregivers' hands and pockets. And the Exo Iris release—curiously—enticed more cybervisitors than Philips' ongoing sleep therapy device troubles (perhaps readers are growing weary of the saga?). A ProPublica and Pittsburgh Gazette investigation claims the company knew about the health risks of its degraded PE-PUR sound abatement foam in its respiratory devices as early as 2010—11 years before it became a major recall. ProPublica claims that Philips received reports early on warning of “black particles” or “dirt and dust” inside the devices’ airway chambers, yet withheld most of the warnings from the FDA "to protect its marquee products as stock prices soared to the highest level in decades."